Brief: Relmada Therapeutics Q1 EPS USD -0.72
08/05/2024 21:06
May 08 (Reuters) - Relmada Therapeutics Q1 cash & investments USD 83.6 million. * Q1 net income USD -21.8 million
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million